Cargando…
ONO‐7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human study
AIMS: The objectives of this study were to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of ONO‐7684, a novel activated factor XI (FXIa) inhibitor, in healthy subjects. METHODS: This was a first‐in‐human (FIH), randomised, placebo‐contr...
Autores principales: | Beale, Dominic, Dennison, Jeremy, Boyce, Malcolm, Mazzo, Francesca, Honda, Naoki, Smith, Paul, Bruce, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359378/ https://www.ncbi.nlm.nih.gov/pubmed/33450079 http://dx.doi.org/10.1111/bcp.14732 |
Ejemplares similares
-
SHR2285, the first selectively oral FXIa inhibitor in China: Safety, tolerability, pharmacokinetics and pharmacodynamics combined with aspirin, clopidogrel or ticagrelor
por: Ma, Tingting, et al.
Publicado: (2022) -
SAT-430 A Phase 1 Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of ONO-5788: A Novel Oral Small Molecule Somatostatin Receptor Type-2 Agonist
por: Kaviya, Arpeat, et al.
Publicado: (2019) -
Enabling accurate measurement of activated factor XI (FXIa) in therapeutic immunoglobulin products
por: Wilmot, Helen V., et al.
Publicado: (2020) -
Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
por: Peterschmitt, M. Judith, et al.
Publicado: (2020) -
Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of
Tirabrutinib (GS-4059/ONO-4059) Target Engagement
por: Yu, Helen, et al.
Publicado: (2018)